These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 4702294)
1. [Anti-androgenic therapy for prostate carcinoma]. Schoonees R S Afr Med J; 1973 May; 47(17):722-4. PubMed ID: 4702294 [No Abstract] [Full Text] [Related]
2. Antiandrogen effects on canine prostatic secretion. Schoonees R; Reynoso G; De Klerk JN; Murphy GP Invest Urol; 1973 May; 10(6):434-7. PubMed ID: 4704168 [No Abstract] [Full Text] [Related]
3. Analysis of the anti-androgenic effect of a new diphenylethylene derivate (F 63) and diethylstilbestrol (DES). Johnson L; Nylander G; Wikström S Acta Soc Med Ups; 1967; 72(5):313-30. PubMed ID: 5628588 [No Abstract] [Full Text] [Related]
4. The effect of androgen on canine prostatic secretion. Schoonees R; Reynoso G; Murphy GP J Surg Oncol; 1972; 4(3):169-79. PubMed ID: 5069801 [No Abstract] [Full Text] [Related]
5. Cyproterone acetate in the treatment of advanced carcinoma of the prostate. Smith RB; Walsh PC; Goodwin WE J Urol; 1973 Jul; 110(1):106-8. PubMed ID: 4713345 [No Abstract] [Full Text] [Related]
6. Use of cyproterone acetate in animal and clinical trials. Neumann F Gynecol Invest; 1971; 2(1):150-79. PubMed ID: 4949823 [No Abstract] [Full Text] [Related]
7. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma. Goldenberg SL; Bruchovsky N; Rennie PS; Coppin CM J Urol; 1988 Dec; 140(6):1460-5. PubMed ID: 2973529 [TBL] [Abstract][Full Text] [Related]
8. Physiologic basis for hormonal theapy in carcinoma of the prostate. Walsh PC Urol Clin North Am; 1975 Feb; 2(1):125-40. PubMed ID: 48206 [No Abstract] [Full Text] [Related]
9. The composition of nerve induced canine prostatic secretion. Smith ER; Lebeaux M Invest Urol; 1971 Sep; 9(2):100-3. PubMed ID: 5165999 [No Abstract] [Full Text] [Related]
10. Comparative effects and mechanisms of castration, estrogen anti-androgen, and anti-estrogen-induced regression of accessory sex organ epithelium and muscle. Neubauer B; Blume C; Cricco R; Greiner J; Mawhinney M Invest Urol; 1981 Jan; 18(4):229-34. PubMed ID: 7451082 [TBL] [Abstract][Full Text] [Related]
11. Experience in the treatment of prostatic carcinoma with cyproterone acetate. Wein AJ; Murphy JJ J Urol; 1973 Jan; 109(1):68-70. PubMed ID: 4684552 [No Abstract] [Full Text] [Related]
12. Effects of oestrogen on phosphatase activity in the ventral prostate of intact, castrated, and androgen-treated castrated, adult rats. Andersson M; Müntzing J Acta Pharmacol Toxicol (Copenh); 1971; 30(3):193-202. PubMed ID: 5171939 [No Abstract] [Full Text] [Related]
13. Clinical-pharmacological investigation of cyproterone acetate. van Wayjen RG; van den Ende A Gynecol Invest; 1971; 2(1):282-9. PubMed ID: 5161488 [No Abstract] [Full Text] [Related]
14. The effect of cyproterone acetate on advanced carcinoma of the prostate. Geller J; Vazakas G; Fruchtman B; Newman H; Nakao K; Loh A Surg Gynecol Obstet; 1968 Oct; 127(4):748-58. PubMed ID: 5675191 [No Abstract] [Full Text] [Related]
15. Effects of ethinylestradiol and cyproterone acetate on androgen metabolism by the human prostate gland. Briggs MH; Briggs M J Clin Endocrinol Metab; 1973 Mar; 36(3):600-4. PubMed ID: 4685394 [No Abstract] [Full Text] [Related]
16. Reversible inhibition of spermatogenesis in men. Petry R; Mauss J; Rausch-Stroomann JG; Vermeulen A Horm Metab Res; 1972 Sep; 4(5):386-8. PubMed ID: 4645935 [No Abstract] [Full Text] [Related]
17. Initiation of LHRH monotherapy for prostate cancer. Milsted RA Prog Clin Biol Res; 1989; 303():69-74. PubMed ID: 2528742 [No Abstract] [Full Text] [Related]